Patent · US Active

Highly phosphorylated and sulfated recombinant factor IX

US7575897B2 · kind B2 · utility

6Cited by

0References

6Claims

0Family size

Assignees

Baxter International Inc. · US
Baxter Healthcare SA · CH

Inventors

Friedrich Scheiflinger · Wien, AT
Ernst Boehm · Dingolfing, DE
Michele Himmelspach · Port, CH
Olaf Merkel · Salzburg, AT

Key dates

Filing date	Mar 28, 2008
Grant date	Aug 18, 2009
Priority date	—
Expiry date	Mar 28, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y304/21022
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a purified recombinant blood coagulation factor IX (rFIX) preparation, wherein at least 25% of the rFIX in the preparation is fully phosphorylated and sulfated, a cell culture expressing a rFIX resulting in said preparation, a pharmaceutical composition for treating a bleeding disorder comprising said preparation, and a method for treating a bleeding disorder comprising the step of administering said preparation to a patient in need thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.